Results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy were examined by a secondary analysis of the historic RTOG 9202 prostate cancer trial. It concluded that there were no additional benefits when compared to short-term hormonal therapy. The research was presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Men with advanced prostate cancer typically receive hormonal ...You have just read an article categorized health
titled Overall Survival Doesn't Improve On Use Of Long-term Hormonal Therapy in Intermediate-risk PCa Patients.
Written by:
editor - Wednesday, October 2, 2013
There are currently no comments for "Overall Survival Doesn't Improve On Use Of Long-term Hormonal Therapy in Intermediate-risk PCa Patients"
Post a Comment